The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
Open accessAbstract
PURPOSE: Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials.gov identifier: NCT03081689 ). The 3-year overall survival (OS) and circulating tumor DNA (ctDNA) analysis have not been reported. METHODS: This was an open-label, multicenter, single-arm, phase II trial in which patients with stage IIIA NSCLC, who were deemed to be surgically resectable, were treated with neoadjuvant paclitaxel (200 mg/m 2 once a day) and carboplatin (area under curve 6) plus nivolumab (360 mg) once on day 1 of each 21-day cycle, for three cycles, followed by adjuvant nivolumab monotherapy for 1 year (240 mg once every 2 weeks for 4 months, followed by 480 mg once every 4 weeks for 8 months). The 3-year OS and ctDNA analysis were secondary objectives of the trial. RESULTS: OS at 36 months was 81.9% (95% CI, 66.8 to 90.6) in the intention-to-treat population, rising to 91.0% (95% CI, 74.2 to 97.0) in the per-protocol population. Neither tumor mutation burden nor programmed cell death ligand-1 staining was predictive of survival. Conversely, low pretreatment levels of ctDNA were significantly associated with improved progression-free survival and OS (hazard ratio [HR], 0.20; 95% CI, 0.06 to 0.63, and HR, 0.07; 95% CI, 0.01 to 0.39, respectively). Clinical responses according to RECIST v1.1 criteria did not predict survival outcomes. However, undetectable ctDNA levels after neoadjuvant treatment were significantly associated with progression-free survival and OS (HR, 0.26; 95% CI, 0.07 to 0.93, and HR, 0.04; 95% CI, 0.00 to 0.55, respectively). The C-index to predict OS for ctDNA levels after neoadjuvant treatment (0.82) was superior to that of RECIST criteria (0.72). CONCLUSION: The efficacy of neoadjuvant chemotherapy plus nivolumab in resectable NSCLC is supported by 3-year OS. ctDNA levels were significantly associated with OS and outperformed radiologic assessments in the prediction of survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 2×
“Likewise, ctDNA clearance was associated with pCR in the CheckMate 816 trial.20 In addition, it is well established that conventional imaging cannot always reliably predict long-term OS in patients undergoing immunotherapy and it has been shown that immunotherapy-based treatments can significantly improve OS rather th…”
BackgroundHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationNivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Evaluating the Yield of Medical Tests
Harrell, F. E. (1982) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1982.03320430047030 · Cited by 3,490
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Paz-Ares, L., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30641-0 · Cited by 1,366
Self-citationGadgeel, S., Rodríguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., Hui, R., Hochmair, M. J., Clingan, P., Powell, S. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03136 · Cited by 1,116
Self-citationSurvival Analysis Part I: Basic concepts and first analyses
Clark, T. G., Bradburn, M. J., Love, S. B., & Altman, D. G. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601118 · Cited by 1,030
Provencio, M., Nadal, E., Insa, A., García-Campelo, M. R., Casal-Rubio, J., Dómine, M., Majem, M., Rodríguez-Abreu, D., Martínez-Martí, A., De Castro Carpeño, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30453-8 · Cited by 841
Self-citationHellmann, M. D., Chaft, J. E., William, W. N., Rusch, V., Pisters, K. M. W., Kalhor, N., Pataer, A., Travis, W. D., Swisher, S. G., & Kris, M. G. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70334-6 · Cited by 646
Cottrell, T. R., Thompson, E. D., Forde, P. M., Stein, J. E., Duffield, A. S., Anagnostou, V., Rekhtman, N., Anders, R. A., Cuda, J. D., Illei, P. B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy218 · Cited by 592
Treatment of Stage III Non-small Cell Lung Cancer
Ramnath, N., Dilling, T. J., Harris, L. J., Kim, A. W., Michaud, G. C., Balekian, A. A., Diekemper, R., Detterbeck, F. C., & Arenberg, D. A. (2013) · Chest · doi:10.1378/chest.12-2360 · Cited by 442
Menzies, A. M., Amaria, R. N., Rozeman, E. A., Huang, A. C., Tetzlaff, M. T., van de Wiel, B. A., Lo, S., Tarhini, A. A., Burton, E. M., Pennington, T. E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01188-3 · Cited by 436
Bellmunt, J., Hussain, M., Gschwend, J. E., Albers, P., Oudard, S., Castellano, D., Daneshmand, S., Nishiyama, H., Majchrowicz, M., Degaonkar, V., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00004-8 · Cited by 429
Rothschild, S. I., Zippelius, A., Eboulet, E. I., Savic Prince, S., Betticher, D., Bettini, A., Früh, M., Joerger, M., Lardinois, D., Gelpke, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00276 · Cited by 333
Anagnostou, V., Forde, P. M., White, J. R., Niknafs, N., Hruban, C., Naidoo, J., Marrone, K., Sivakumar, I. K. A., Bruhm, D. C., Rosner, S., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1127 · Cited by 318
Mauguen, A., Pignon, J.-P., Burdett, S., Domerg, C., Fisher, D., Paulus, R., Mandrekar, S. J., Belani, C. P., Shepherd, F. A., Eisen, T., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70158-x · Cited by 246
Analysis of Survival by Tumor Response and Other Comparisons of Time-to-Event by Outcome Variables
Anderson, J. R., Cain, K. C., & Gelber, R. D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1000 · Cited by 228
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
Blumenthal, G. M., Bunn, P. A., Chaft, J. E., McCoach, C. E., Perez, E. A., Scagliotti, G. V., Carbone, D. P., Aerts, H. J. W. L., Aisner, D. L., Bergh, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.017 · Cited by 184
Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade
Stein, J. E., Lipson, E. J., Cottrell, T. R., Forde, P. M., Anders, R. A., Cimino-Mathews, A., Thompson, E. D., Allaf, M. E., Yarchoan, M., Feliciano, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2379 · Cited by 177
Qu, Y., Emoto, K., Eguchi, T., Aly, R. G. M., Zheng, H., Chaft, J. E., Tan, K. S., Jones, D. R., Kris, M. G., Adusumilli, P. S., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.017 · Cited by 125
Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?
Yang, M., Forbes, M. E., Bitting, R. L., O’Neill, S. S., Chou, P. C., Topaloĝlu, Ü., Miller, L. D., Hawkins, G. A., Grant, S. C., DeYoung, B. R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx766 · Cited by 108
Forde, P. M., Spicer, J. D., Lü, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S., Brahmer, J. R., Swanson, S., et al. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-ct003 · Cited by 103
Self-citationFlamier, A., Abdouh, M., Hamam, R., Barabino, A., Patel, N., Gao, A. Y. L., Hanna, R., & Bernier, G. (2020) · npj Precision Oncology · doi:10.1038/s41698-019-0106-1 · Cited by 95
Pairawan, S. S., Hess, K. R., Jankú, F., Sánchez, N., Shaw, K. R. M., Eng, C., Damodaran, S., Javle, M. M., Kaseb, A. O., Hong, D. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0306 · Cited by 87
Leprieur, E. G., Herbretau, G., Duménil, C., Julié, C., Giraud, V., Labrune, S., Dumoulin, J., Tisserand, J. C., Emile, J., Blons, H., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1424675 · Cited by 86
Data maturity and follow-up in time-to-event analyses
Gebski, V., Garès, V., Gibbs, E., & Byth, K. (2018) · International Journal of Epidemiology · doi:10.1093/ije/dyy013 · Cited by 84
Casarrubios, M., Cruz‐Bermúdez, A., Nadal, E., Insa, A., Campelo, M. R. G., Lázaro-Quintela, M., Dómine, M., Majem, M., Rodríguez‐Abreu, D., Martínez‐Martí, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1200 · Cited by 78
Self-citationLing, Y., Li, N., Li, L., Guo, C., Wei, J., Yuan, P., Tan, F., Tao, X., Wang, S., Wang, Z., et al. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00135-2 · Cited by 60
Briviesca, R. L., Cruz‐Bermúdez, A., Nadal, E., Insa, A., García-Campelo, R., Huidobro, G., Dómine, M., Majem, M., Rodríguez‐Abreu, D., Martínez‐Martí, A., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.491 · Cited by 54
Self-citationLung cancer patients with COVID-19 in Spain: GRAVID study
Provencio, M., Gallego, J. M. M., Calles, A., Antoñanzas, M., Pangua, C., Mielgo-Rubio, X., Nadal, E., Castro, R. L., Martín, A. L., del Barco, E., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.05.014 · Cited by 40
Self-citationProvencio, M., Serna‐Blasco, R., Franco, F., Calvo, V., Royuela, A., Auglytė, M., Sánchez-Hernández, A., Campayo, M. D. J., Girón, C. G., Dómine, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.031 · Cited by 36
Self-citationCovariate‐adjusted measures of discrimination for survival data
White, I. R., Rapsomaniki, E., & for the Emerging Risk Factors Collaboration (2015) · Biometrical Journal · doi:10.1002/bimj.201400061 · Cited by 13 · cited 1×
“The discrimination ability for each model was evaluated using Harrell’s concordance index (C-index).(14,15) The C-index can take values from 0 to 1, with higher values indicating better discrimination.”
Method
Cited by
Perioperative Nivolumab in Resectable Lung Cancer
Cascone, T., Awad, M. M., Spicer, J. D., He, J., Lu, S., Sepesi, B., Tanaka, F., Taube, J. M., Cornelissen, R., Havel, L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2311926 · Cited by 527
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., DeCamp, M., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0020 · Cited by 498
Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer
Provencio, M., Nadal, E., González-Larriba, J. L., Martínez-Martí, A., Bernabé, R., Bosch-Barrera, J., Casal-Rubio, J., Calvo, V., Insa, A., Ponce, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2215530 · Cited by 484
Self-citationNeoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Topalian, S. L., Forde, P. M., Emens, L. A., Yarchoan, M., Smith, K. N., & Pardoll, D. M. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.011 · Cited by 317
Minimal residual disease as a target for liquid biopsy in patients with solid tumours
Pantel, K., & Alix-Panabières, C. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00967-y · Cited by 146
Metadata
- Authors
- Provencio, M., Serna-Blasco, R., Nadal, E., Insa, A., García-Campelo, M. R., Casal Rubio, J., Dómine, M., Majem, M., Rodríguez-Abreu, D., Martínez-Martí, A., De Castro Carpeño, J., Cobo, M., López Vivanco, G., Del Barco, E., Bernabé Caro, R., Viñolas, N., Barneto Aranda, I., Viteri, S., Pereira, E., Royuela, A., Calvo, V., Martín-López, J., García-García, F., Casarrubios, M., Franco, F., Sánchez-Herrero, E., Massuti, B., Cruz-Bermúdez, A., & Romero, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-09-01
- Volume
- 40
- Issue
- 25
- Pages
- 2924-2933
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4280554654
- Cited by
- 349
- References
- 40
- FWCI
- 43.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.